Live Breaking News & Updates on Kurome Therapeutics Board

Stay updated with breaking news from Kurome therapeutics board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Kurome Therapeutics Closes $15M in Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time! ....

United States , Jan Rosenbaum , Daniel Starczynowski , Daniel Heller , Aaron Kantoff , Blood Diseases Institute , Hematologic Malignancies Program At Cincinnati Children Cancer , Bruce Crippen Photography , Kurome Therapeutics , Affinity Asset Advisors , Venture Partner , General Partner , Chief Investment Officer , Kurome Therapeutics Board , Hematologic Malignancies Program , Cincinnati Children , ஒன்றுபட்டது மாநிலங்களில் , ஜான் ரோசன்பாம் , டேனியல் ஹெல்லர் , இரத்தம் நோய்கள் நிறுவனம் , துணிகர கூட்டாளர் , ஜநரல் கூட்டாளர் , தலைமை முதலீடு அதிகாரி , ஸிந்ஸந்யாடீ குழந்தைகள் ,

Kurome Therapeutics closes $15 million Series A financing

Credit: CincyTech
Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing.
The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors.
We are excited to have the support of exceptional investors. This financing allows us to expand our R&D program to substantially de-risk compound selection as we identify our first development candidate in advance of IND filing, said Kurome Chief Executive Officer and Chief Scientific Officer Jan Rosenbaum, PhD. ....

United States , Jan Rosenbaum , Daniel Starczynowski , Daniel Heller , Aaron Kantoff , Blood Diseases Institute , National Center , Hematologic Malignancies Program At Cincinnati Children Cancer , National Institutes Of Health , Cincinnati Children Hospital Medical Center , Translational Sciences , Kurome Therapeutics , Affinity Asset Advisors , Kurome Chief Executive Officer , Chief Scientific Officer Jan Rosenbaum , Hematologic Malignancies Program , Cincinnati Children , General Partner , Chief Investment Officer , Affinity Asset , Hospital Medical Center , National Institutes , Advancing Translational Sciences , Venture Partner , Kurome Therapeutics Board , Cell Biology ,